广西地区三类人群EB病毒潜伏膜蛋白2特异性细胞免疫状态的研究  

Analysis of EB virus LMP2 specific immune status among three groups in Guangxi area

作　　者：邓卓霞 王勇利[1] 杜海军[2] 司勇锋[1] 兰桂萍[1] 孙金杰[1] 杨涌[1] 韩星[1] 

机构地区：[1]广西壮族自治区人民医院耳鼻咽喉头颈肿瘤科,南宁530021 [2]中国疾病预防控制中心病毒病预防控制所传染病预防控制国家重点实验室,北京100052

出　　处：《中华实验和临床病毒学杂志》2016年第2期194-198,共5页Chinese Journal of Experimental and Clinical Virology

基　　金：广西自然科学基金（2011GXNSFA018235）;广西科技攻关计划项目（14124003-3、14279008）

摘　　要：目的 初步探讨广西地区鼻咽癌患者、血清VCA/IgA阳性高危人群及血清VCA/IgA阴性健康人群EB病毒LMP2特异性细胞免疫状态的差异.方法 选择广西苍梧地区经血清学筛查VCA/IgA阳性高危人群志愿者60例,对照为血清VCA/IgA筛查阴性的健康志愿者20例,同时选取广西壮族自治区人民医院经病理确诊鼻咽癌患者134例,分离外周血单个核细胞（PBMC）,采用酶联免疫斑点法（ELISPOT）检测外周血中LMP2特异性细胞毒性T淋巴细胞（CTL）免疫水平.比较鼻咽癌患者与健康志愿者、高危人群外周血LMP2特异性CTL免疫状态的差异.结果 鼻咽癌患者LMP2特异性CTL免疫水平明显低于健康志愿者及血清EB病毒抗体阳性人群,差异有统计学意义（P＜0.01）;血清EB病毒抗体阳性三种不同滴度人群间LMP2特异性T细胞免疫反应差异有统计学意义（P=0.002）;鼻咽癌Ⅰ、Ⅱ期患者同Ⅲ期及Ⅳ期患者的LMP2特异性T细胞免疫反应存在差异（P＜0.01）.结论 三类人群间LMP2特异性CTL水平的差异可能是导致EB病毒长期潜伏感染并导致鼻咽癌发生的重要原因,针对LMP2的特异性免疫治疗有望降低鼻咽癌的发生率.Objective To investigate the difference of EB-LMP2 specific immune status among patients with nasopharyngeal carcinoma,serum EBV VCA/IgA positive group and EBV VCA/IgA negative group in Guangxi area of china.Methods 60 cases of serum EBV VCA/IgA screening positive volunteers and 20 cases of negative volunteers came from Cangwu county in Guangxi area,and 134 cases of patients volunteers with nasopharyngeal carcinoma （NPC） came from The People＇s Hospital of Guangxi Zhuang Autonomous Region.Blood samples were taken before any treatment,and the preipheral blood mononuclear cels（PBMC） were taken by Ficoll density gradient centrifugation.Specific immune responses of cytotoxic T lymphocytes （CTLs） were measured using IFN-γ ELISPOT assays with HLA-matched LMP2 epitope peptides.Results LMP2 specific immune responses levels in nasopharyngeal carcinoma patients were significantly lower than those healthy volunteers and serum EBV VCA/IgA screening positive volunteers （P 〈 0.01）,and the immune responses were statistically different in three VCA/IgA titers （1∶5,1∶10 and 1∶20 or more,P =0.002）;LMP2 specific immune responses in early stage patients of nasopharyngeal carcinoma （stage Ⅰ/Ⅱ） were better than those advanced stage （stage Ⅲ and stage Ⅳ） （P 〈 0.01）.Conclusions The difference of LMP2 specific CTL levels among three groups may be the important reason for the long-term latent infection of EB virus and lead to the occurrence of nasopharyngeal carcinoma,and LMP2 specific immunotherapy is expected to reduce the incidence of nasopharyngeal carcinoma.

关 键 词：鼻咽癌 EB病毒 LMP2 ELISPOT 特异性细胞毒性T淋巴细胞(CTL) 免疫治疗 

分 类 号：R739.63[医药卫生—肿瘤]